Portfolio

PTM Therapeutics

Antibody therapeutic for the treatment of inflammatory bowel disease
(2020)

Refraction AI, Inc

Robotic platform for providing safe and scalable goods delivery in urban areas
(2020)

S3D Precision Dispensing, Inc

Enabling digital manufacturing; dispensing lubricants, OLED materials and bio-fluids with micron-scale features onto existing surfaces
(2020)

Smart Production Systems

Automating managerial decision-making on the factory floor
(2020)

Zakuro

Safer solid-state batteries with double the energy density of Li-ion batteries
(2020)

Angio Insight

Automated analysis of angiograms to augment clinical decisions in managing coronary artery disease
(2019)

Applied Morphomics Inc

Applied Morphomics, Inc. is a biomarker technology and development company targeting assessment of body factors essential for delivering precision medicine.
(2019)

Arcascope

Apps developed using mathematical modeling to predict circadian rhythms to improve performance and wellness.
(2019)

Cellf BIO LLC

Cellf BIO manufactures bioengineered sphincters using autologous progenitor cells that replace the dysfunctional internal anal sphincter, the root cause of FI. This new product, called a BioSphincterTM, allows the patient to regain full control of bowel movements and rejuvenate their quality of life.
(2019)

CubeWorks

CubeWorks is accelerating the future of IoT through millimeter-scale smart sensing solutions. CubeWorks leads revolutionary advances in ultra-low power computing through its CubiSens™ Platform, the world's smallest wireless smart sensors, unmatched in longevity, intelligence, accuracy, value, and ease of use.
(2019)

DGD Pharmaceuticals

Mutant EGFR inhibitor for various cancer types
(2019)

Equarius

FinTech tools for water risk pricing in public equities
(2019)

GreenMark Biomedical

To enable oral healthcare professionals to preserve teeth through earlier diagnosis & non-invasive treatment.
(2019)

HiPer Fiber

Advanced steel fibers to reinforce ultra-high-performance concrete
(2019)

Immulus

Next-generation biomanufacture of cell therapies
(2019)

InheRET

Risk evaluation tool uses your personal and family health history to find out if you are at increased risk for hereditary disease using easy-to-read report with next-step recommendations helps you and your doctor make a care plan to reduce your risk
(2019)

MakeMedical

Surgeon designed, high fidelity, 3D printed surgical simulators
(2019)

MEKanistic Therapeutics

MEKanistic is innovating cancer therapies by advancing a novel class of selective kinase inhibitors rationally designed to target both EGFR and PI3K with a single molecule. This breakthrough design expands the therapeutic window while avoiding inherent toxicity challenges of multi-compound treatments. Preclinical studies of its lead drug MTX-531 show a high incidence of tumor regression with dramatically reduced toxicity. EGFR, PI3 kinase dual inhibitor (precision pharmacology)
(2019)